Clinical Trial Update: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors [Phase 2]

View source ↗

Summary

This document provides an update on the Phase 2 trial of pemigatinib in non-muscle invasive bladder cancer patients with recurrent low- or intermediate-risk tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Bladder Cancer, NMIBC | Phase 2 | Status: COMPLETED